Bioheart Inc. (BHRT) 0.0240 $BHRT
Bioheart Releases Q2 Financial Information Showing Growth
Marketwire - Thu Aug 07, 7:04AM CDT
Bioheart, Inc. (OTCQB: BHRT) released today financial information based on results from Q2 2014. The financial data shows that Bioheart has grown in product revenues, increased income, reduced debt, and further strengthened the financial standing of the company.
Bioheart Announces World's First Combination Stem Cell Treatment
Marketwire - Thu Jul 24, 7:23AM CDT
Bioheart, Inc. (OTCQB: BHRT) announced today that it has completed the world's first combination stem cell treatment with Magnum Cell Therapies (Magnum) in Honduras. A patient with congestive heart failure has been treated with a combination of AdipoCell(TM) or adipose derived stem cells and MyoCell(R) or muscle derived stem cells. AdipoCell may help to promote angiogenesis or new blood vessel formation in ischemic tissue while MyoCell may help to promote myogenesis or new muscle formation. The cells were delivered directly into the damaged areas of the heart using the MyoCath(R) Catheter.
Bioheart Announces Grand Opening of Magnum Cell Therapies
Marketwire - Wed Jul 16, 7:02AM CDT
Bioheart, Inc. (OTCQB: BHRT) announced today that it will participate in the grand opening event of Magnum Cell Therapies (Magnum) in Honduras during the week of July 21st. Bioheart has previously announced the joint venture with Magnum and the goal to bring regenerative therapies to patients in South America.
Bioheart Announces Clinical Trials in India
Marketwire - Mon Jul 07, 7:01AM CDT
Bioheart, Inc. (OTCQB: BHRT) announced today that they have begun two clinical trials in India including the first ever combination stem cell trial in the world. The first cardiac patient has successfully been enrolled and treated in India using AdipoCell(TM) or adipose derived stem cells. The second trial will involve the combination of AdipoCell and MyoCell(R) or muscle derived stem cells for congestive heart failure patients. AdipoCell may help to promote angiogenesis or new blood vessel formation in ischemic tissue while MyoCell may help to promote myogenesis or new muscle formation.
Bioheart Announces Joint Venture in South Africa
Marketwire - Tue Jun 24, 7:01AM CDT
Bioheart, Inc. (OTCBB: BHRT), a biotechnology company focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of degenerative diseases, announced today that it has entered into a joint venture with Dr. Walter Bell of South Africa.
Bioheart to Present at SELECTBIO Clinical Translation of Stem Cells
Marketwire - Wed Apr 02, 7:03AM CDT
Bioheart, Inc. (OTCQB: BHRT), a biotechnology company focused on the discovery, development and commercialization of autologous cell therapies, announced that it will present at the SELECTBIO 2nd Annual Clinical Translation of Stem Cells on April 21st, 2014. The conference brings together basic scientists, clinician-scientists, as well as medical practitioners/surgeons focusing on studying, characterizing, and deploying various classes of stem cells for therapeutic utility.
Bioheart Announces Clinical Study for Degenerative Disc Disease
Marketwire - Wed Mar 26, 1:16PM CDT
Bioheart, Inc. (OTCQB: BHRT), a biotechnology company focused on the discovery, development and commercialization of autologous cell therapies, announced that it will enroll patients in a new study for degenerative disc disease (DDD). The study will enroll up to 100 patients to determine the safety and efficacy of adipose derived stem cells or AdipoCell(TM) in patients with DDD.
Bioheart, Inc. Announces Mike Tomas, President/CEO, Has Been Chosen as an Honoree for Emerge Americas Techweek100 Miami 2014
Marketwire - Tue Mar 25, 7:03AM CDT
Bioheart, Inc. (OTCQB: BHRT), a biotechnology company focused on the discovery, development and commercialization of autologous cell therapies, announced that Mike Tomas, President and CEO, has been named as one of the top 100 technology leaders on eMerge Americas Techweek100 Miami 2014. (http://techweek.com/miami/techweek100/).
Bioheart, Inc. to Present at American Association of Orthopedic Medicine on Cell Therapy
Marketwire - Fri Mar 21, 7:01AM CDT
Bioheart, Inc. (OTCQB: BHRT), a biotechnology company focused on the discovery, development and commercialization of autologous cell therapies, announced that it will present at the 31st American Association of Orthopedic Medicine Annual Conference (AAOM) Conference and Scientific Seminar. Co-sponsored by the American Board of Quality Assurance and Utilization Review Physicians, Inc. (ABQAURP), the conference, titled "Sports, Spine and Beyond: Latest Advances in Regenerative Orthopedic Medicine," will focus on the newest breakthroughs in the field of orthopedic medicine.
Galena Biopharma Inc. Share Value Tumbles on News of SEC Investigation
ACCESSWIRE - Wed Mar 19, 10:25AM CDT
Galena Biopharma Inc. (NASDAQ:GALE) share volume soared Mar. 18, with more than 17,653,116 shares changing hands, nearly double its three-month average volume of 9,373,933 shares, while its share value continued to tumble, closing at $2.82, down 40 cents, or 12.42%, from its closing price of $3.22 the previous day. The high volume and stock value tumble are being triggered by the Worcester, Mass-based company's revelation that it is being investigated by the Securities and Exchange Commission. Here is the company's statement: "In February 2014, we learned that the SEC is investigating certain matters relating to our company and an outside investor-relations firm that we retained in 2013. We have been in contact with the SEC staff through our counsel and are cooperating with the investigation," the company stated in its 10-K filing dated Mar. 17. Class-Acton Lawsuits In addition to this bad news, the company is facing a slew of class action lawsuits from stockholders that allege Galena and certain of its executives issued a series of materially false and misleading statements during the Class Period, violating federal securities laws. However, it should be noted that none of these allegations have been proven. Moreover, Galena's results for its fourth quarter were less than comforting to shareholders. Its earnings per share loss of (46c) on revenue of $1.32M as compared to estimates of (9c) and $1.62M, respectively. The company pointed out that the Q4 net loss of $48.5M included $38.9M in non-cash charges. On the positive side, the company lifted its 2014 Abstral net revenue estimates to $11M-$15M as compared to prior guidance of $8M-$12M. Analysts' Consensus Nonetheless, of the 9 analyst firms that cover Galena, 7 rate it a "strong buy," 1 a "buy" and 1 a "sell." Find out what could be the best investor's move when it comes to GALE by getting the complete report here, or by cutting and pasting the following link in your Web browser: http://www.sixfigurestockpicks.com Bioheart Inc.'s Stock Volume Soars on News of Joint Venture with Magnum Cell Therapies Meanwhile, development-stage, biotechnology company Bioheart Inc.'s (OTCQB: BHRT) stock volume continued to soar Mar. 18, with 7,457,880 shares changing hands, nearly three times more than its three-month average volume of 2,607,553 shares.
Bioheart Announces Joint Venture With Magnum Cell Therapies
Marketwire - Mon Mar 17, 7:19AM CDT
Bioheart, Inc. (OTCQB: BHRT), a biotechnology company focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of degenerative diseases, announced today that it has entered into a joint venture with Magnum Cell Therapies (http://www.magnumterapiacelular.com/).
Generex Biotechnology Corp. Granted Patents on New HPV and Influenza Vaccines
ACCESSWIRE - Wed Mar 12, 11:01AM CDT
Generex Biotechnology Corp. (OTCQB: GNBT) stock volume soared Mar. 11, with 9,325,106 shares changing hands, significantly higher than its three-month average volume of 7,012,285 shares.
Bioheart Boosts Team With Regulatory, Finance and Administrative Expertise
Marketwire - Fri Sep 20, 12:10PM CDT
Bioheart (OTCQB: BHRT), a leader in developing stem cell therapies to treat cardiovascular diseases, has expanded its team by adding three key strategic positions with regulatory, finance and administrative expertise.
Bioheart Inc adds Sheldon T Anderson to board
M2 - Thu Aug 29, 6:05AM CDT
Biotech company Bioheart Inc (OTCQB:BHRT) stated on Wednesday that Sheldon T Anderson has been named to its board of directors.
Sheldon T. Anderson Elected to the Board of Directors of Bioheart, Inc.
Marketwire - Wed Aug 28, 7:02AM CDT
Sheldon T. Anderson has been elected to the Board of Directors of Bioheart, Inc. (OTCQB: BHRT), a biotech company focused on the discovery, development and commercialization of autologous cell therapies for the treatment of chronic and acute heart damage as well as severe peripheral vascular disease. Mr. Anderson is Chairman of the Advisory Board of Northern Trust. He retired last year as Chairman and CEO of the Southeast Region of Northern Trust, where he was responsible for managing the company's investment management, trust and estate planning, private and business banking and financial consulting business in Florida and Georgia.
Bioheart's President / CEO Mike Tomas Appointed to Workforce Florida Board of Directors by Governor Rick Scott
Marketwire - Wed Aug 14, 7:21AM CDT
Bioheart, Inc. (OTCQB: BHRT) announced today that Mike Tomas, the company's President/CEO, has been appointed to serve on Workforce Florida's Board of Directors for a four year term by Florida Governor Rick Scott. Tomas is one of 15 Floridians appointed to the Board of Directors. Workforce Florida is charged with overseeing the state's workforce system and developing strategies that will improve the state's business environment while supporting its economy (www.EmployFlorida.com).
OTC Daily Alert Stock Watch - Bioheart (OTCBB:BHRT)
WorldStockWire - Tue Aug 13, 12:00PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
Bioheart Inc wins validated FDA registration for stem tissue bank establishment
M2 - Mon Aug 12, 5:56AM CDT
Cardiovascular cell technology company Bioheart Inc (OTCQB:BHRT) said on Friday that it has been awarded a validated registration from the FDA for the initial tissue bank listing.
Bioheart Receives Validated FDA Registration for Tissue Bank Establishment
Marketwire - Fri Aug 09, 7:01AM CDT
Bioheart, Inc. (OTCQB: BHRT) announced today that it received a validated registration from the FDA for the initial tissue bank listing. Bioheart is offering stem cell storage for patients enrolled in the studies at the centers of excellence outside the US. This new business unit will create an additional revenue stream for Bioheart. Patients can store stem cell doses in liquid nitrogen for future use in approved clinical trials. These trials focus on the use of LipiCell(TM) (adipose derived stem cells) in a variety of different degenerative diseases.
Bioheart Announces Phase III MIRROR Trial for MyoCell Initiated
Marketwire - Tue Jul 02, 2:38PM CDT
Bioheart, Inc. (OTCQB: BHRT) announced today the successful enrollment and randomization of the first patient in the Phase III MIRROR Trial using MyoCell(R) or muscle derived stem cells.
Bioheart Releases Q2 Financial Information Showing Growth
Marketwire - Thu Aug 07, 7:04AM CDT
Bioheart, Inc. (OTCQB: BHRT) released today financial information based on results from Q2 2014. The financial data shows that Bioheart has grown in product revenues, increased income, reduced debt, and further strengthened the financial standing of the company.
Bioheart Announces World's First Combination Stem Cell Treatment
Marketwire - Thu Jul 24, 7:23AM CDT
Bioheart, Inc. (OTCQB: BHRT) announced today that it has completed the world's first combination stem cell treatment with Magnum Cell Therapies (Magnum) in Honduras. A patient with congestive heart failure has been treated with a combination of AdipoCell(TM) or adipose derived stem cells and MyoCell(R) or muscle derived stem cells. AdipoCell may help to promote angiogenesis or new blood vessel formation in ischemic tissue while MyoCell may help to promote myogenesis or new muscle formation. The cells were delivered directly into the damaged areas of the heart using the MyoCath(R) Catheter.
Bioheart Announces Grand Opening of Magnum Cell Therapies
Marketwire - Wed Jul 16, 7:02AM CDT
Bioheart, Inc. (OTCQB: BHRT) announced today that it will participate in the grand opening event of Magnum Cell Therapies (Magnum) in Honduras during the week of July 21st. Bioheart has previously announced the joint venture with Magnum and the goal to bring regenerative therapies to patients in South America.
Bioheart Announces Clinical Trials in India
Marketwire - Mon Jul 07, 7:01AM CDT
Bioheart, Inc. (OTCQB: BHRT) announced today that they have begun two clinical trials in India including the first ever combination stem cell trial in the world. The first cardiac patient has successfully been enrolled and treated in India using AdipoCell(TM) or adipose derived stem cells. The second trial will involve the combination of AdipoCell and MyoCell(R) or muscle derived stem cells for congestive heart failure patients. AdipoCell may help to promote angiogenesis or new blood vessel formation in ischemic tissue while MyoCell may help to promote myogenesis or new muscle formation.
Bioheart Announces Joint Venture in South Africa
Marketwire - Tue Jun 24, 7:01AM CDT
Bioheart, Inc. (OTCBB: BHRT), a biotechnology company focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of degenerative diseases, announced today that it has entered into a joint venture with Dr. Walter Bell of South Africa.
Bioheart to Present at SELECTBIO Clinical Translation of Stem Cells
Marketwire - Wed Apr 02, 7:03AM CDT
Bioheart, Inc. (OTCQB: BHRT), a biotechnology company focused on the discovery, development and commercialization of autologous cell therapies, announced that it will present at the SELECTBIO 2nd Annual Clinical Translation of Stem Cells on April 21st, 2014. The conference brings together basic scientists, clinician-scientists, as well as medical practitioners/surgeons focusing on studying, characterizing, and deploying various classes of stem cells for therapeutic utility.
Bioheart Announces Clinical Study for Degenerative Disc Disease
Marketwire - Wed Mar 26, 1:16PM CDT
Bioheart, Inc. (OTCQB: BHRT), a biotechnology company focused on the discovery, development and commercialization of autologous cell therapies, announced that it will enroll patients in a new study for degenerative disc disease (DDD). The study will enroll up to 100 patients to determine the safety and efficacy of adipose derived stem cells or AdipoCell(TM) in patients with DDD.
Bioheart, Inc. Announces Mike Tomas, President/CEO, Has Been Chosen as an Honoree for Emerge Americas Techweek100 Miami 2014
Marketwire - Tue Mar 25, 7:03AM CDT
Bioheart, Inc. (OTCQB: BHRT), a biotechnology company focused on the discovery, development and commercialization of autologous cell therapies, announced that Mike Tomas, President and CEO, has been named as one of the top 100 technology leaders on eMerge Americas Techweek100 Miami 2014. (http://techweek.com/miami/techweek100/).
Bioheart, Inc. to Present at American Association of Orthopedic Medicine on Cell Therapy
Marketwire - Fri Mar 21, 7:01AM CDT
Bioheart, Inc. (OTCQB: BHRT), a biotechnology company focused on the discovery, development and commercialization of autologous cell therapies, announced that it will present at the 31st American Association of Orthopedic Medicine Annual Conference (AAOM) Conference and Scientific Seminar. Co-sponsored by the American Board of Quality Assurance and Utilization Review Physicians, Inc. (ABQAURP), the conference, titled "Sports, Spine and Beyond: Latest Advances in Regenerative Orthopedic Medicine," will focus on the newest breakthroughs in the field of orthopedic medicine.
Galena Biopharma Inc. Share Value Tumbles on News of SEC Investigation
ACCESSWIRE - Wed Mar 19, 10:25AM CDT
Galena Biopharma Inc. (NASDAQ:GALE) share volume soared Mar. 18, with more than 17,653,116 shares changing hands, nearly double its three-month average volume of 9,373,933 shares, while its share value continued to tumble, closing at $2.82, down 40 cents, or 12.42%, from its closing price of $3.22 the previous day. The high volume and stock value tumble are being triggered by the Worcester, Mass-based company's revelation that it is being investigated by the Securities and Exchange Commission. Here is the company's statement: "In February 2014, we learned that the SEC is investigating certain matters relating to our company and an outside investor-relations firm that we retained in 2013. We have been in contact with the SEC staff through our counsel and are cooperating with the investigation," the company stated in its 10-K filing dated Mar. 17. Class-Acton Lawsuits In addition to this bad news, the company is facing a slew of class action lawsuits from stockholders that allege Galena and certain of its executives issued a series of materially false and misleading statements during the Class Period, violating federal securities laws. However, it should be noted that none of these allegations have been proven. Moreover, Galena's results for its fourth quarter were less than comforting to shareholders. Its earnings per share loss of (46c) on revenue of $1.32M as compared to estimates of (9c) and $1.62M, respectively. The company pointed out that the Q4 net loss of $48.5M included $38.9M in non-cash charges. On the positive side, the company lifted its 2014 Abstral net revenue estimates to $11M-$15M as compared to prior guidance of $8M-$12M. Analysts' Consensus Nonetheless, of the 9 analyst firms that cover Galena, 7 rate it a "strong buy," 1 a "buy" and 1 a "sell." Find out what could be the best investor's move when it comes to GALE by getting the complete report here, or by cutting and pasting the following link in your Web browser: http://www.sixfigurestockpicks.com Bioheart Inc.'s Stock Volume Soars on News of Joint Venture with Magnum Cell Therapies Meanwhile, development-stage, biotechnology company Bioheart Inc.'s (OTCQB: BHRT) stock volume continued to soar Mar. 18, with 7,457,880 shares changing hands, nearly three times more than its three-month average volume of 2,607,553 shares.
Bioheart Announces Joint Venture With Magnum Cell Therapies
Marketwire - Mon Mar 17, 7:19AM CDT
Bioheart, Inc. (OTCQB: BHRT), a biotechnology company focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of degenerative diseases, announced today that it has entered into a joint venture with Magnum Cell Therapies (http://www.magnumterapiacelular.com/).
Generex Biotechnology Corp. Granted Patents on New HPV and Influenza Vaccines
ACCESSWIRE - Wed Mar 12, 11:01AM CDT
Generex Biotechnology Corp. (OTCQB: GNBT) stock volume soared Mar. 11, with 9,325,106 shares changing hands, significantly higher than its three-month average volume of 7,012,285 shares.
Bioheart Boosts Team With Regulatory, Finance and Administrative Expertise
Marketwire - Fri Sep 20, 12:10PM CDT
Bioheart (OTCQB: BHRT), a leader in developing stem cell therapies to treat cardiovascular diseases, has expanded its team by adding three key strategic positions with regulatory, finance and administrative expertise.
Bioheart Inc adds Sheldon T Anderson to board
M2 - Thu Aug 29, 6:05AM CDT
Biotech company Bioheart Inc (OTCQB:BHRT) stated on Wednesday that Sheldon T Anderson has been named to its board of directors.
Sheldon T. Anderson Elected to the Board of Directors of Bioheart, Inc.
Marketwire - Wed Aug 28, 7:02AM CDT
Sheldon T. Anderson has been elected to the Board of Directors of Bioheart, Inc. (OTCQB: BHRT), a biotech company focused on the discovery, development and commercialization of autologous cell therapies for the treatment of chronic and acute heart damage as well as severe peripheral vascular disease. Mr. Anderson is Chairman of the Advisory Board of Northern Trust. He retired last year as Chairman and CEO of the Southeast Region of Northern Trust, where he was responsible for managing the company's investment management, trust and estate planning, private and business banking and financial consulting business in Florida and Georgia.
Bioheart's President / CEO Mike Tomas Appointed to Workforce Florida Board of Directors by Governor Rick Scott
Marketwire - Wed Aug 14, 7:21AM CDT
Bioheart, Inc. (OTCQB: BHRT) announced today that Mike Tomas, the company's President/CEO, has been appointed to serve on Workforce Florida's Board of Directors for a four year term by Florida Governor Rick Scott. Tomas is one of 15 Floridians appointed to the Board of Directors. Workforce Florida is charged with overseeing the state's workforce system and developing strategies that will improve the state's business environment while supporting its economy (www.EmployFlorida.com).
OTC Daily Alert Stock Watch - Bioheart (OTCBB:BHRT)
WorldStockWire - Tue Aug 13, 12:00PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
Bioheart Inc wins validated FDA registration for stem tissue bank establishment
M2 - Mon Aug 12, 5:56AM CDT
Cardiovascular cell technology company Bioheart Inc (OTCQB:BHRT) said on Friday that it has been awarded a validated registration from the FDA for the initial tissue bank listing.
Bioheart Receives Validated FDA Registration for Tissue Bank Establishment
Marketwire - Fri Aug 09, 7:01AM CDT
Bioheart, Inc. (OTCQB: BHRT) announced today that it received a validated registration from the FDA for the initial tissue bank listing. Bioheart is offering stem cell storage for patients enrolled in the studies at the centers of excellence outside the US. This new business unit will create an additional revenue stream for Bioheart. Patients can store stem cell doses in liquid nitrogen for future use in approved clinical trials. These trials focus on the use of LipiCell(TM) (adipose derived stem cells) in a variety of different degenerative diseases.
Bioheart Announces Phase III MIRROR Trial for MyoCell Initiated
Marketwire - Tue Jul 02, 2:38PM CDT
Bioheart, Inc. (OTCQB: BHRT) announced today the successful enrollment and randomization of the first patient in the Phase III MIRROR Trial using MyoCell(R) or muscle derived stem cells.
